-
Amneal names SVP, general counsel
BRIDGEWATER, N.J. — Amneal Pharmaceuticals has named a drug industry attorney as SVP and general counsel, the generic drug maker said Thursday.
Amneal announced the appointment of Robert Loewenstein, who previously served as head of law firm Budd Larner, P.C.’s corporate generic pharmaceuticals practice.
-
Decision Resources: J&J, Merck chemotherapy drugs will emerge as go-to second-line treatments
BURLINGTON, Mass. — Chemotherapy drugs made by Johnson & Johnson and Merck will become the standard second-line treatment for ovarian cancer within the decade, replacing a treatment made by Bristol-Myers Squibb and generic versions, according to a new report by market research firm Decision Resources.